Biosimilars for Rheumatoid Arthritis: Riding the 2023 Wave [Podcast]

Abstract

Stanley B Cohen,1,* Mariah Z Leach2,* 1Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA; 2Mamas Facing Forward, Louisville, Colorado, USA*These authors contributed equally to this workCorrespondence: Stanley B Cohen, Email [email protected]: This article discusses some of the queries and concerns that patients may have about initiating or switching to treatment with a biosimilar for rheumatoid arthritis following the US 2023 release of several biosimilars of the adalimumab reference product, also known by the brand name, Humira. The article also covers the difference between a generic medicine and a biosimilar, and the clinical evidence to support the safety and efficacy of adalimumab biosimilars in patients with rheumatoid arthritis.Keywords: biosimilars, interchangeability, rheumatoid arthritis

Keywords

• biosimilars
• interchangeability
• rheumatoid arthritis